Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human PCSK9 (D374Y), Avi Tag (Avitag™), His-Tag, 25µg  

Recombinant Biotinylated Human PCSK9 (D374Y), Avi Tag (Avitag™), His-Tag, 25µg

Recombinant, Biotinylated Human PCSK9 (D374Y), Gln 31 - Gln 692, expressed from human HEK293 cells, Avi tag (Avitag™), His-Tag

Synonym: recombinant, human, biotinylated, protein, PCSK9, FH3, HCHOLA3, LDLCQ1, NARC1, PC9

More details

PCY-H82E7-25

Availability: within 7 days

455,00 €

Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9), is an enzyme which in humans is encoded by the PCSK9 gene. This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. PCSK9 may also have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a rare form of autosomal dominant familial hypercholesterolemia (HCHOLA3).Especially,the D374Y mutation results in higher affinity of PCSK9 for LDLR.

Source
MABSol® Recombinant Biotinylated Human PCSK9 (D374Y), Avitag,His Tag (PCY-H82E7) is expressed from human HEK293 cells. It contains AA Gln 31 - Gln 692 (Accession # Q8NBP7-1 (D374Y)).
Predicted N-terminus: Gln 31

Molecular Characterization
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. This protein undergoes autocatalytic cleavage to release the pro-peptide and mature chain. The pro-peptide and mature chain are associated through non‑covalent interactions and with a calculated MW of 13.8 kDa and 59.9 kDa respectively. The protein migrates as 17 kDa and 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. The D374Y mutation results in higher affinity of PCSK9 for LDLR.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio

Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by reduced SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Safety of Statins and Nonstatins for Treatment of Dyslipidemia"
Newman
Endocrinol Metab Clin North Am (2022) 51 (3), 655-679
(2) "Evaluation and Management of Lipids and Lipoproteins in Children and Adolescents"
Patel, Patni
Endocrinol Metab Clin North Am (2022) 51 (3), 573-588
(3) "Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy"
Golledge, Fernando, Armstrong
Drugs (2022)
Showing 1-3 of 4780 papers.